Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Oncolytics Biotech Inc ONCY


Primary Symbol: T.ONC

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Post by canadafanon Jun 11, 2024 4:45pm
261 Views
Post# 36083488

Multiple thoughts.

Multiple thoughts.

thanks again noteable for exaplsing the variou approval pathways.
Ultimately, the approval for Pelareorep be marketed is the only goal.
onc mangemet did not on their own randomly decide to bring about Bracelrt, Aware-1, or Gobblet.
All were initiated at request if FDA & the various colaborators. Pfizer, Roche, Incyte.
The PanCan organization etc etc.
There are many outside eyes watching & validating the various trials & outcomes.
One reason Noteable needs to repeat things as a few side show band of bashers, either collectively have an I.Q. That of a baked potato, or just continue to throw out random distractions.
Granted there are legitimate concerns. Saying phase 3 could have been started 3 years ago, ..or when ever? 
it was at the time when they were granted FDA fast track for MBc, that things were looking full speed ahead.
it was clearly discussed at the time to de- risk the trials , the FDA advised a window of opportunity study to identify pre- full- on treatment, a biomarker.
Aware-1, & subsequent trials have indntified two.
That being after 2 weeks , a blood draw will indicate if the patient can respond or not to Pela.
That very science, is the partial request of the FDA type C meeting.
in plain language, they can reduce patient numbers, (/saves $$), and reduce overall length if trail ( saves $$) and ..the derisking part.
Simple, yet very significant.
pre- screening non- responders, can statistically increase the efficacy Benefits.
hence..de- risking the phase 3 trial.
THAT, came from advice from FDA.
build the best trial possible, with the best pre- trial screening. Thereby reducing the likelihood of trial failure.
regretably has taken more time.
Now?
Axe soon as FDA responds, the MBc phase 3 trial will be in concept ready to roll.
next step?
who will be the partner to move that forward.
if I was one of those with a few billion $ at risk. I'd wait until the FDA responded.
Having as much info as reasonably possible.
That is good business & good science.
The Gobblet , pancreatic , anal etc was an added bonus in the wait.
I respect , Noteable for his tenacity.
memem keeps asking about a date. Like the old records that kept skipping. 
The date will be when we see a N.R. With details. 
Not far away.
 


 

 

<< Previous
Bullboard Posts
Next >>